Clinical Trials Browser

Adenocarcinoma Of Esophagus, Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT03751761 2024-02-28

GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study

Phase 1/2 Completed

58 enrolled

Gastrointestinal

Stomach Neoplasms

NCT06255262 2024-02-13

Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Phase 1/2 Unknown

30 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT03376659 2024-02-05

Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma

Phase 1/2 Terminated

8 enrolled 14 charts

Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

NCT03618134 2023-11-18

Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

Phase 1/2 Terminated

19 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms

NCT05451173 2023-10-03

Combining ICI With SBRT or HypoFrx-RT for ES NSCLC

Phase 1/2 Unknown

83 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03522584 2023-06-12

Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1/2 Terminated

6 enrolled 8 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04696848 2023-04-21

The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors

Phase 1/2 Terminated

25 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04646837 2023-03-29

Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models

Phase 1/2 Unknown

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04124991 2023-03-16

SOLID

Phase 1/2 Completed

24 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03202758 2023-02-10

MEDITREME

Phase 1/2 Completed

57 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT02963831 2022-12-22

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

Phase 1/2 Completed

67 enrolled 16 charts

GastrointestinalGynecologic

Appendiceal Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

Clinical Trials

ADAPT-BLADDER

STERIMGLI

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers

Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab

CAMILLA

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

SOLARA

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial

LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer

A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

SEPION

Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma

ABIMMUNE

Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer

ICRA

DURIPANC

MOVIE

SYNERGY

DURANCE

DUART

B-IMMUNE

ICC

COMPASS-TNBC

DUTRELASCO

Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study

Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma

Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

Combining ICI With SBRT or HypoFrx-RT for ES NSCLC

Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors

Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models

SOLID

MEDITREME

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies